-First clinical evaluation of BB-025, designed to rapidly and specifically reverse BB-031 activity, advancing Basking's goal to redefine thrombosis treatment- RESEARCH TRIANGLE, N.C., Nov. 12, 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback